In this article, we review the data about the expression of BRD4 in patients with inflammatory bowel diseases (IBDs) and patients with colorectal cancer (CRC) and discuss the more recent findings supporting the therapeutic benefit of BRD4 inhibitors in both IBD- and CRC-like mouse models. This evidence concerns the gene BRD4 and colorectal carcinoma.